Clinical trials: Androgen Deprivation Therapy
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
- Trial name
- NCT02796898
- Testing
- SM88 (Cohort 1), SM88 (Cohort 2)
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tyme, Inc
Prostate Cancer
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- DASL-HiCaP (NCT04136353)
- Testing
- Darolutamide, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
- Where
- 93 sites in United States, Australia and 4 more
- Volunteers
- 1,100 people
- Sponsor
- University of Sydney
Prostate Cancer
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
The purpose of this study is to determine whether treatment with Zactima for up to 18 months will prolong the off-treatment interval in patients who are undergoing intermittent androgen deprivation therapy.
- Trial name
- ZENITH (NCT00686036)
- Testing
- vandetanib
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Cancer
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
- Trial name
- GAINPCCONTROL (NCT06908694)
- Testing
- Semaglutide Pen Injector
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer, Cardiovascular Death
Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
The purpose of this study is to review cause of death in patients undergoing prostate brachytherapy at a single institution. Furthermore, we are analyzing patients undergoing androgen deprivation therapy and whether or not this…
- Trial name
- NCT00651222
- Testing
- No intervention was required
- Where
- United States
- Sponsor
- Prostate Cancer Foundation of Chicago
Salivary Gland Carcinoma
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not…
- Trial name
- NCT03942653
- Testing
- Goserelin Acetate, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Manish Patel
Prostate Cancer
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
- Trial name
- NCT00245466
- Testing
- Degarelix
- Volunteers
- 88 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
FIRMAGON® Intensive Drug Monitoring
To evaluate the safety profile of FIRMAGON® (to fulfill the regulatory authority's requirement of Intensive Drug Monitoring in Chinese participants with prostate cancer need androgen deprivation therapy [ADT] treated with…
- Trial name
- NCT05181800
- Testing
- Degarelix Cohort
- Where
- China
- Volunteers
- 1,454 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms, Exercise
Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC). The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased…
- Conditions
- Prostatic Neoplasms, Exercise, Soccer Training, Androgen Deprivation Therapy
- Trial name
- NCT01711892
- Testing
- Soccer training
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Copenhagen
Prostate Cancer
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy, such as bicalutamide, leuprolide, and goserelin, may lessen the amount of androgens made by the body.
- Trial name
- NCT00771017
- Testing
- GVAX prostate cancer vaccine, bicalutamide, goserelin
- Sponsor
- Eastern Cooperative Oncology Group
Salivary Gland Cancer
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers.
- Trial name
- NCT01969578
- Testing
- bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
This study will evaluate if adding the investigational drug Dovitinib to standard androgen ablation therapy (ADT) is beneficial in prolonging the time to disease progression in patients with metastatic prostate cancer who are…
- Trial name
- NCT02065323
- Testing
- Standard ADT, Dovitinib
- Where
- United States
- Sponsor
- Oscar Goodman, Jr.
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited…
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Trial name
- SPARKLE (NCT07650240)
- Testing
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Mayo Clinic
Oligometastatic Prostate Cancer
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen DeprIvation therapy in metachronous prostate cancer OligometaStAsis).
- Trial name
- RADIOSA (NCT03940235)
- Testing
- Androgen deprivation therapy (ADT), SBRT
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Prostatic Adenocarcinoma
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
Although surgical or medical castration (i.e., androgen-deprivation therapy, ADT) is considered standard treatment in metastatic castration-naïve PC (mCNPC) patients, current guidelines have established the addition docetaxel or…
- Trial name
- NCT06015321
- Testing
- Enzalutamide
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation…
- Trial name
- NCT05879913
- Testing
- Coronary CT Angiography (CCTA)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
Recurrent Prostate Cancer
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable through diet modification alone.
- Trial name
- NCT03496805
- Testing
- MGE, ADT
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer Metastatic
Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)
Patients with primary diagnosed metastatic prostate cancer are randomly divided into two groups. One group receive standard of care ADT continually. Another group receive ADT plus prostate cryotherapy.
- Trial name
- NCT03129854
- Testing
- prostate cryotherapy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003124
- Testing
- flutamide, leuprolide acetate, radiation therapy
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.
- Trial name
- NCT04869371
- Testing
- Docetaxel injection, Triptorelin Pamoate for Injectable Suspension, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hongqian Guo